Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets hidden cancer cells after colorectal cancer treatment

NCT ID NCT06617858

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests the drug AMB-05X in 15 colorectal cancer patients who have completed curative treatment but still have signs of cancer in their blood (ctDNA-positive) with no visible tumors on scans. The goal is to see if the drug can safely eliminate these remaining cancer cells and prevent recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AMB-05X (a drug given by IV)
What this could lead to
If it works, this could help eliminate remaining cancer cells in patients with colorectal cancer who have no visible tumors but show signs of minimal residual disease.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply broadly. The drug may cause side effects or fail to clear the ctDNA.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COLORECTAL CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • The University of Texas MD Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.